Other ways to search: Events Calendar | UTHSC | UTHSC News

Research Funding


  1. PI: R01CA276152-01 (NIH/NCI)     Tiffany Seagroves (MPI)     4/2023-3/2028

“Targeting brain and bone metastases in metastatic breast cancer for improved patient survival”.

Total direct cost $1,996,410. Total cost: $3,074,470

2. PI: 1R01CA148706 (NIH/NCI)     Duane D. Miller (Co-I: 2011-2015; MPI: 2016-2026)          

“Targeting the colchicine site in tubulin for cancer therapy”. Current funding period (2021-2026) total cost: $1.96 million. Total funding awarded for this project $5.7 million.

3. PI: 1R01CA240447 (NIH/NCI)                Muxiang Zhou (MPI)        7/2020-6/2025

“Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer”. Total cost: $2.72 million.

4. PI: HT9425-23-1-0216        Junming Yue (Co-PI)      7/2023-6/2027

“Development of an Orally Available and Low-Toxic Chemotherapy for Improved Ovarian Cancer Therapy”

Total award $924,000.

5. MPI: 1R61NS124923 (NIH/NINDS)      Jianxiong Jiang (contact MPI) and Wei Li (MPI)      12/2021-11/2024
“Targeting TRPC3 Channels for Epileptic Seizures”. Total cost: $1.15 million.

6. MPI: 1RF1AG072703 (NIH/NIA)    Liao (contact PI); Li and Bhaskar (MPIs)    4/2022-3/2027

Validation of a novel tau clearance mechanism”

First three years of the award total $2,157,183 for 6/1/2022-5/31/2025. The remaining award is possible after a satisfactory progress report at the end of the third year. Five-year total expected cost: about $3.6 million.

7. PI: BC190092 (DoD)                    Tiffany Seagroves (Partner PI)                    3/2020-2/2024

DoD Breast Cancer Research Program

Total budget: $2,269,056 for the duration of 3 years

W81XWH2010011: Li’s part of the project  $1,271,866

W81XWH2010019: Seagroves’ part (Partner-PI) of the project  $997,190 

“Discovery of orally bioavailable tubulin inhibitors to overcome taxane resistance in metastatic breast cancer”

8. PI: R41NS135658-01 (NIH/NINDS)         9/2023-8/2024

“Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment”

Awarded to SEAK Therapeutics, LLC, total cost $429,932.

9. Co-I: 1R24EY029950-01A1 (NIH/NEI)           Monica Jablonski (PI)      3/2020-2/2025

“Novel Extended Release Glaucoma Therapy for Once Daily Dosing” Total cost: $4.94 million.

10. Co-I: 1R01NS128336-01           Ram Mahato (PI)     7/15/2022-5/31/2027

“Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma”

Total amount: $2,391,270.   Amount to the Li lab: $38,115/year for a total of $190,575.

Role: subcontract PI.


Currently none.


Please see the relevant sections in the CV.